Afuresertib (GSK2110183), an orally active ATP-competitive inhibitor of all three isoforms of AKT, has exhibited a favorable activity profile in bortezomib-refractory MM patients [104]. This evidence concerns the gene AKT1 and Miyoshi myopathy.